 Lyra Therapeutics, Inc. LYRA, a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that the company is set to join the small cap Russell 2000 Index and the broad-market Russell 3000 Index at the conclusion of this years reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 29, 2020, according to a preliminary list of additions posted June 5, 2020. We are pleased that Lyra will be included in the Russell 2000 and 3000 indexes, and we believe this will increase the overall awareness of, and exposure to, our stock among the investment community, said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra Therapeutics. 